Sulodexide Treatment in Patients With Dense Deposit Disease
Status:
Withdrawn
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if a medicine called Sulodexide will help prevent or slow
down the progression of Membranoproliferative Glomerulonephritis type II/Dense Deposit
Disease. Sulodexide is not yet FDA approved and has not been studied in children.
Study aim/hypotheses: to measure the efficacy of Sulodexide treatment in patients with the
above disease/s.